R1 RCM Inc. (NASDAQ:RCM – Get Free Report) has been assigned an average recommendation of “Hold” from the eighteen ratings firms that are covering the firm, MarketBeat.com reports. Thirteen equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $15.41.
RCM has been the topic of a number of research reports. Leerink Partnrs downgraded R1 RCM from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. Deutsche Bank Aktiengesellschaft lifted their price target on shares of R1 RCM from $14.00 to $16.00 and gave the company a “hold” rating in a research report on Tuesday, July 9th. Stephens lowered shares of R1 RCM from an “overweight” rating to an “equal weight” rating in a research report on Thursday, August 1st. Jefferies Financial Group lowered shares of R1 RCM from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Leerink Partners cut shares of R1 RCM from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $17.00 to $14.30 in a research report on Thursday, August 1st.
Check Out Our Latest Stock Report on RCM
Institutional Trading of R1 RCM
R1 RCM Stock Performance
Shares of RCM stock opened at $14.21 on Wednesday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.84 and a current ratio of 1.84. The firm has a market capitalization of $5.99 billion, a price-to-earnings ratio of -177.63 and a beta of 0.85. R1 RCM has a one year low of $8.87 and a one year high of $15.12. The company has a 50 day moving average price of $14.06 and a 200 day moving average price of $13.05.
R1 RCM (NASDAQ:RCM – Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The healthcare provider reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.03. The business had revenue of $627.90 million during the quarter, compared to the consensus estimate of $633.10 million. R1 RCM had a negative return on equity of 1.44% and a negative net margin of 1.68%. The firm’s revenue was up 12.0% on a year-over-year basis. Sell-side analysts anticipate that R1 RCM will post -0.24 EPS for the current year.
About R1 RCM
R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.
Further Reading
- Five stocks we like better than R1 RCM
- How to Choose Top Rated Stocks
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- What is a Secondary Public Offering? What Investors Need to Know
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- Financial Services Stocks Investing
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.